Researchers involved with this research team are looking at different chemical and biological approaches to the discovery and development of cancer therapies. Chemical agents refer to synthetic molecules, small peptides or natural products, whereas biological therapies use the patient’s immune system, either directly or indirectly, to fight cancer or to lessen the side effects that may be caused by some cancer treatments. Experts in cancer biology, cancer pharmacology, organic chemistry, molecular modeling and radiobiology exploit the genomic and proteomic technologies as well as the best bioinformatics tools with the overarching goal to develop “smart” drugs against key targets for therapeutic intervention.
Theme Leader:Dr. Jian Hui Wu, Lady Davis Institute for Medical Research, 91
Members:
Dr. Moulay Alaoui-Jamali, Lady Davis Institute for Medical Research, 91
Dr. Raquel Aloyz, Lady Davis Institute for Medical Research, 91
Dr. Richard Béliveau, Université du Quebec a Montréal
Dr. Katherine Borden, Université de Montréal
Dr. Marc Fabian, Lady Davis Institute for Medical Research, 91
Dr. Sylvie Mader, Université de Montréal
Dr. Koren Mann, Lady Davis Institute for Medical Research, 91
Dr. Thierry Muanza, Lady Davis Institute for Medical Research, 91
Dr. Lawrence Panasci, Lady Davis Institute for Medical Research, 91
Dr. Michael Pollak, Lady Davis Institute for Medical Research, 91
Dr. Stephane Richard, Lady Davis Institute for Medical Research, 91
Dr. Siham Sabri, Research Institute 91 Health Centre
Dr. Uri Saragovi, Lady Davis Institute for Medical Research, 91
Dr. Ivan Topisirovic, Lady Davis Institute for Medical Research, 91
Dr. Mark Trifiro, Lady Davis Institute for Medical Research, 91
Dr. Josie Ursini-Siegel, Lady Davis Institute for Medical Research, 91
Dr. John White, Lady Davis Institute for Medical Research, 91
Dr. Michael Witcher, Lady Davis Institute for Medical Research, 91